All NICE products on chronic kidney disease. Includes any guidance, advice and quality standards.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Published guidance on this topic (24)
Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.
Published advice on this topic (3)
Set out priority areas for quality improvement in health and social care.
Published quality standards on this topic (2)
Review the evidence across broad health and social care topics.
Reviews the clinical and cost-effectiveness of new treatments.
Review new diagnostic technologies for adoption in the NHS.
Assessments of whether procedures are safe enough and work well enough for wider use in the NHS.
Review the evidence and likely costs of medical devices and technologies.
Guidance, quality standards and advice being developed.
Guidance and quality standards awaiting development.
Guidance in topic selection.
NICE has today (15 May) published 2 new rapid COVID-19 guidelines. The first is on chronic kidney disease (CKD) and the second on interstitial lung disease.
Examples of how our guidance and standards have been put into practice in the NHS, local authorities, voluntary sector and a range of other organisations.
Showing 2 of 2 shared learning examples for this topic: